Thomas Jefferson University

Takami Sato

TitleProfessor
InstitutionThomas Jefferson University
DepartmentMedical Oncology
Address1015 Walnut St.
Philadelphia PA 19107
Phone215-955-1752
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Chua V, Lopez-Anton M, Baqai U, Purwin TJ, Haj JI, Waltrich FJ, Trachtenberg I, Luo K, Tudi R, Jeon A, Han A, Chervoneva I, Davies MA, Aguirre-Ghiso JA, Sato T, Aplin AE. Slow proliferation of BAP1-deficient uveal melanoma cells is associated with reduced S6 signaling and resistance to nutrient stress. Sci Signal. 2024 Jun 11; 17(840):eadn8376. PMID: 38861613.
      Citations:    
    2. Sacco JJ, Carvajal RD, Butler MO, Shoushtari AN, Hassel JC, Ikeguchi A, Hernandez-Aya L, Nathan P, Hamid O, Piulats JM, Rioth M, Johnson DB, Luke JJ, Espinosa E, Leyvraz S, Collins L, Holland C, Sato T. Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma. J Immunother Cancer. 2024 Jun 06; 12(6). PMID: 38844408.
      Citations:    
    3. Terai M, Sato T. Individualised neoantigen cancer vaccine therapy. Lancet. 2024 Jan 18. PMID: 38246193.
      Citations:    
    4. Robbins J, Halegoua-DeMarzio D, Basu Mallick A, Vijayvergia N, Ganetzky R, Lavu H, Giri VN, Miller J, Maley W, Shah AP, DiMeglio M, Ambelil M, Yu R, Sato T, Lefler DS. Liver Transplantation in a Woman with Mahvash Disease. N Engl J Med. 2023 Nov 23; 389(21):1972-1978. PMID: 37991855.
      Citations:    
    5. Han A, Mukha D, Chua V, Purwin TJ, Tiago M, Modasia B, Baqai U, Aumiller JL, Bechtel N, Hunter E, Danielson M, Terai M, Wedegaertner PB, Sato T, Landreville S, Davies MA, Kurtenbach S, Harbour JW, Schug ZT, Aplin AE. Co-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth. Cancers (Basel). 2023 Jun 30; 15(13). PMID: 37444561.
      Citations:    
    6. Lapadula D, Lam B, Terai M, Sugase T, Tanaka R, Farias E, Kadamb R, Lopez-Anton M, Heine CC, Modasia B, Aguirre-Ghiso JA, Aplin AE, Sato T, Benovic JL. IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression. Mol Cancer Ther. 2023 01 03; 22(1):63-74. PMID: 36223548.
      Citations:    
    7. Orloff M, Seedor R, Sato T. Review of bi-specific therapies in uveal melanoma. Cancer Gene Ther. 2022 Mar 02. PMID: 35236927.
      Citations:    
    8. Shields CL, Dockery PW, Mayro EL, Bas Z, Yaghy A, Lally SE, Orloff M, Sato T, Shields JA. Conditional survival of uveal melanoma using The Cancer Genome Atlas (TCGA) classification (Simplified Version) in 1001 cases. Saudi J Ophthalmol. 2022 Jul-Sep; 36(3):308-314. PMID: 36276251.
      Citations:    
    9. Terai M, Shimada A, Chervoneva I, Hulse L, Danielson M, Swensen J, Orloff M, Wedegaertner PB, Benovic JL, Aplin AE, Sato T. Prognostic Values of G-Protein Mutations in Metastatic Uveal Melanoma. Cancers (Basel). 2021 Nov 17; 13(22). PMID: 34830903.
      Citations:    
    10. Seedor RS, Orloff M, Sato T. Genetic Landscape and Emerging Therapies in Uveal Melanoma. Cancers (Basel). 2021 Nov 02; 13(21). PMID: 34771666.
      Citations:    
    11. Tanaka R, Terai M, Londin E, Sato T. The Role of HGF/MET Signaling in Metastatic Uveal Melanoma. Cancers (Basel). 2021 Oct 30; 13(21). PMID: 34771620.
      Citations:    
    12. Anikeeva N, Panteleev S, Mazzanti NW, Terai M, Sato T, Sykulev Y. Efficient killing of tumor cells by CAR-T cells requires greater number of engaged CARs than TCRs. J Biol Chem. 2021 Sep; 297(3):101033. PMID: 34371020.
      Citations:    
    13. Terai M, Kageyama K, Sugase T, Lam BQ, Alexeev V, Sato T. Orthotopic Human Metastatic Uveal Melanoma Xenograft Mouse Models: Applications for Understanding the Pathophysiology and Therapeutic Management of Metastatic Uveal Melanoma. Curr Protoc. 2021 Apr; 1(4):e110. PMID: 33882197.
      Citations:    
    14. Ohara M, Saito K, Kageyama K, Terai M, Cheng H, Aplin AE, Sato T. Dual Targeting of CDK4/6 and cMET in Metastatic Uveal Melanoma. Cancers (Basel). 2021 Mar 04; 13(5). PMID: 33806615.
      Citations:    
    15. Han A, Purwin TJ, Bechtel N, Liao C, Chua V, Seifert E, Sato T, Schug ZT, Speicher DW, Harbour JW, Aplin AE. Correction to: BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors. Oncogene. 2021 Mar; 40(9):1753. PMID: 33510355.
      Citations:    
    16. Han A, Purwin TJ, Bechtel N, Liao C, Chua V, Seifert E, Sato T, Schug ZT, Speicher DW, William Harbour J, Aplin AE. BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors. Oncogene. 2020 Nov 18. PMID: 33208912.
      Citations:    
    17. Orloff M, Brennan M, Sato S, Shields CL, Shields JA, Lally S, Mashayekhi A, Mason J, Materin M, Mastrangelo M, Sato T. Unique geospatial accumulations of uveal melanoma. Am J Ophthalmol. 2020 Jul 15. PMID: 32681908.
      Citations:    
    18. Kabadi RA, Shah M, Marhefka GD, George G, Awsare B, Terai M, Sato T. Rapid, Fatal Acute Right Ventricular Failure After Locoregional Cytokine Therapy for Uveal Melanoma Liver Metastases. Tex Heart Inst J. 2020 Jun 01; 47(3):224-228. PMID: 32997782.
      Citations:    
    19. Sugase T, Lam BQ, Danielson M, Terai M, Aplin AE, Gutkind JS, Sato T. Development and optimization of orthotopic liver metastasis xenograft mouse models in uveal melanoma. J Transl Med. 2020 May 20; 18(1):208. PMID: 32434572.
      Citations:    
    20. Terai M, Londin E, Rochani A, Link E, Lam B, Kaushal G, Bhushan A, Orloff M, Sato T. Expression of Tryptophan 2,3-Dioxygenase in Metastatic Uveal Melanoma. Cancers (Basel). 2020 Feb 10; 12(2). PMID: 32050636.
      Citations:    
    21. Seedor RS, Eschelman DJ, Gonsalves CF, Adamo RD, Orloff M, Amjad A, Sharpe-Mills E, Chervoneva I, Shields CL, Shields JA, Mastrangelo MJ, Sato T. An Outcome Assessment of a Single Institution's Longitudinal Experience with Uveal Melanoma Patients with Liver Metastasis. Cancers (Basel). 2020 Jan 01; 12(1). PMID: 31906411.
      Citations:    
    22. Kageyama K, Ozaki S, Sato T. Generation of a Liver Orthotopic Human Uveal Melanoma Xenograft Platform in Immunodeficient Mice. J Vis Exp. 2019 Nov 06; (153). PMID: 31762467.
      Citations:    
    23. Gonsalves CF, Eschelman DJ, Adamo RD, Anne PR, Orloff MM, Terai M, Hage AN, Yi M, Chervoneva I, Sato T. A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis. Radiology. 2019 Aug 27; 190199. PMID: 31453767.
      Citations:    
    24. Londin E, Magee R, Shields CL, Lally SE, Sato T, Rigoutsos I. IsomiRs and tRNA-derived fragments are associated with metastasis and patient survival in uveal melanoma. Pigment Cell Melanoma Res. 2019 Jul 08. PMID: 31283110.
      Citations:    
    25. Snook AE, Baybutt TR, Xiang B, Abraham TS, Flickinger JC, Hyslop T, Zhan T, Kraft WK, Sato T, Waldman SA. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. J Immunother Cancer. 2019 Apr 23; 7(1):104. PMID: 31010434.
      Citations:    
    26. Chua V, Orloff M, Teh JL, Sugase T, Liao C, Purwin TJ, Lam BQ, Terai M, Ambrosini G, Carvajal RD, Schwartz G, Sato T, Aplin AE. Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma. EMBO Mol Med. 2019 Feb; 11(2). PMID: 30610113.
      Citations:    
    27. Lapadula D, Farias E, Randolph CE, Purwin T, McGrath D, Charpentier T, Zhang L, Wu S, Terai M, Sato T, Tall GG, Zhou N, Wedegaertner P, Aplin AE, Aguirre-Ghiso J, Benovic JL. Effects of Oncogenic Gaq and Ga11 Inhibition by FR900359 in Uveal Melanoma. Mol Cancer Res. 2018 Dec 19. PMID: 30567972.
      Citations:    
    28. Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects. Retina. 2018 Apr 23. PMID: 29689030.
      Citations:    
    29. Javed A, Arguello D, Johnston C, Gatalica Z, Terai M, Weight RM, Orloff M, Mastrangelo MJ, Sato T. PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. Immunotherapy. 2017 Dec; 9(16):1323-1330. PMID: 29185395.
      Citations:    
    30. Valsecchi ME, Orloff M, Sato R, Chervoneva I, Shields CL, Shields JA, Mastrangelo MJ, Sato T. Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma: Comparison with Institutional Controls. Ophthalmology. 2018 Feb; 125(2):210-217. PMID: 28935400.
      Citations:    
    31. Kageyama K, Ohara M, Saito K, Ozaki S, Terai M, Mastrangelo MJ, Fortina P, Aplin AE, Sato T. Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis. J Transl Med. 2017 Jun 23; 15(1):145. PMID: 28645290.
      Citations:    
    32. Williams NL, Wuthrick EJ, Kim H, Palmer JD, Garg S, Eldredge-Hindy H, Daskalakis C, Feeney KJ, Mastrangelo MJ, Kim LJ, Sato T, Kendra KL, Olencki T, Liebner DA, Farrell CJ, Evans JJ, Judy KD, Andrews DW, Dicker AP, Werner-Wasik M, Shi W. Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases. Int J Radiat Oncol Biol Phys. 2017 Sep 01; 99(1):22-30. PMID: 28816150.
      Citations:    
    33. Aka AA, Rappaport JA, Pattison AM, Sato T, Snook AE, Waldman SA. Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer. Expert Rev Clin Pharmacol. 2017 May; 10(5):549-557. PMID: 28162021.
      Citations:    
    34. Kemp DM, Pidich A, Larijani M, Jonas R, Lash E, Sato T, Terai M, De Pizzol M, Allegretti M, Igoucheva O, Alexeev V. Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment. Oncotarget. 2017 Feb 28; 8(9):14428-14442. PMID: 28129639.
      Citations:    
    35. Cheng H, Chua V, Liao C, Purwin TJ, Terai M, Kageyama K, Davies MA, Sato T, Aplin AE. Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. Mol Cancer Ther. 2017 Mar; 16(3):516-528. PMID: 28138035.
      Citations:    
    36. Eldredge-Hindy H, Ohri N, Anne PR, Eschelman D, Gonsalves C, Intenzo C, Bar-Ad V, Dicker A, Doyle L, Li J, Sato T. Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma: Clinical Outcomes and the Predictive Value of Fluorodeoxyglucose Positron Emission Tomography. Am J Clin Oncol. 2016 Apr; 39(2):189-95. PMID: 24441583.
      Citations:    
    37. Javed A, Sato S, Sato T. Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldencel-T). Future Oncol. 2016 Mar; 12(6):751-62. PMID: 26837440.
      Citations:    
    38. Orloff M, Weight R, Valsecchi ME, Sato T. Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity? Rev Recent Clin Trials. 2016; 11(2):81-6. PMID: 27028970.
      Citations:    
    39. Ozaki S, Vuyyuru R, Kageyama K, Terai M, Ohara M, Cheng H, Manser T, Mastrangelo MJ, Aplin AE, Sato T. Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization. Am J Pathol. 2016 Jan; 186(1):43-56. PMID: 26613897.
      Citations:    
    40. Terai M, Mu Z, Eschelman DJ, Gonsalves CF, Kageyama K, Chervoneva I, Orloff M, Weight R, Mastrangelo MJ, Cristofanilli M, Sato T. Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells. EBioMedicine. 2015 Nov; 2(11):1821-6. PMID: 26870807.
      Citations:    
    41. Orloff M, Valsecchi ME, Sato T. Successes and setbacks of early investigational drugs for melanoma. Expert Opin Investig Drugs. 2015 Aug; 24(8):993-7. PMID: 26068553.
      Citations:    
    42. Cheng H, Terai M, Kageyama K, Ozaki S, McCue PA, Sato T, Aplin AE. Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma. Cancer Res. 2015 Jul 1; 75(13):2737-48. PMID: 25952648.
      Citations:    
    43. Gonsalves CF, Eschelman DJ, Thornburg B, Frangos A, Sato T. Uveal Melanoma Metastatic to the Liver: Chemoembolization With 1,3-Bis-(2-Chloroethyl)-1-Nitrosourea. AJR Am J Roentgenol. 2015 Aug; 205(2):429-33. PMID: 25905562.
      Citations:    
    44. Valsecchi ME, Terai M, Eschelman DJ, Gonsalves CF, Chervoneva I, Shields JA, Shields CL, Yamamoto A, Sullivan KL, Laudadio M, Berd D, Mastrangelo MJ, Sato T. Double-Blinded, Randomized Phase II Study Using Embolization with or without Granulocyte-Macrophage Colony-Stimulating Factor in Uveal Melanoma with Hepatic Metastases. J Vasc Interv Radiol. 2015 Apr; 26(4):523-532.e2. PMID: 25678394.
      Citations:    
    45. Sato T. Tumor Necrosis Factor-a Blockade and Development of Uveal Melanoma: Expected Adverse Effect or Just Coincidence? Mayo Clin Proc. 2014 Nov; 89(11):1467-70. PMID: 25444483.
      Citations:    
    46. Anikeeva N, Steblyanko M, Fayngerts S, Kopylova N, Marshall DJ, Powers GD, Sato T, Campbell KS, Sykulev Y. Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity. Eur J Immunol. 2014 Aug; 44(8):2331-9. PMID: 24810893.
      Citations:    
    47. Yoshida M, Selvan S, McCue PA, Deangelis T, Baserga R, Fujii A, Rui H, Mastrangelo MJ, Sato T. Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth. Pigment Cell Melanoma Res. 2014 Mar; 27(2):297-308. PMID: 24354797.
      Citations:    
    48. Valsecchi ME, Sato T. The potential role of sunitinib targeting melanomas. Expert Opin Investig Drugs. 2013 Nov; 22(11):1473-83. PMID: 24050392.
      Citations:    
    49. Piana PM, Bar V, Doyle L, Anne R, Sato T, Eschelman DJ, McCann JW, Gonsalves CF, Brown DB. Early arterial stasis during resin-based yttrium-90 radioembolization: incidence and preliminary outcomes. HPB (Oxford). 2014 Apr; 16(4):336-41. PMID: 23782387.
      Citations:    
    50. Eschelman DJ, Gonsalves CF, Sato T. Transhepatic therapies for metastatic uveal melanoma. Semin Intervent Radiol. 2013 Mar; 30(1):39-48. PMID: 24436516.
      Citations:    
    51. Valsecchi ME, Coronel M, Intenzo CM, Kim SM, Witkiewicz AK, Sato T. Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma. Melanoma Res. 2013 Feb; 23(1):33-9. PMID: 23164993.
      Citations:    
    52. Sato T, Terai M, Tamura Y, Alexeev V, Mastrangelo MJ, Selvan SR. Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res. 2011 Dec; 51(2-3):170-82. PMID: 22139852.
      Citations:    
    53. Berger AC, Fierro M, Kairys JC, Berd D, Sato T, Andrel J, Hyslop T, Mastrangelo MJ. Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma. J Surg Oncol. 2012 Jan; 105(1):15-20. PMID: 21815149.
      Citations:    
    54. Khan W, Sullivan KL, McCann JW, Gonsalves CF, Sato T, Eschelman DJ, Brown DB. Moxifloxacin prophylaxis for chemoembolization or embolization in patients with previous biliary interventions: a pilot study. AJR Am J Roentgenol. 2011 Aug; 197(2):W343-5. PMID: 21785063.
      Citations:    
    55. Piana PM, Gonsalves CF, Sato T, Anne PR, McCann JW, Bar Ad V, Eschelman DJ, Parker L, Doyle LA, Brown DB. Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center. J Vasc Interv Radiol. 2011 Oct; 22(10):1373-9. PMID: 21764600.
      Citations:    
    56. Petroziello MF, McCann JW, Gonsalves CF, Eschelman DJ, Anne PR, Sato T, Doyle LA, Frangos A, Brown DB. Side-branch embolization before 90Y radioembolization: rate of recanalization and new collateral development. AJR Am J Roentgenol. 2011 Jul; 197(1):W169-74. PMID: 21700981.
      Citations:    
    57. Mahipal A, Terai M, Berd D, Chervoneva I, Patel K, Mastrangelo MJ, Sato T. Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. Cancer Immunol Immunother. 2011 Jul; 60(7):1039-45. PMID: 21519827.
      Citations:    
    58. Gonsalves CF, Eschelman DJ, Sullivan KL, Anne PR, Doyle L, Sato T. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. AJR Am J Roentgenol. 2011 Feb; 196(2):468-73. PMID: 21257902.
      Citations:    
    59. Nair BC, Williams NC, Cui C, Summers D, Mastrangelo MJ, Hubosky SG, Shields CL, Shields JA, Sato T. Conjunctival melanoma: bladder and upper urinary tract metastases. J Clin Oncol. 2011 Mar 20; 29(9):e216-9. PMID: 21189399.
      Citations:    
    60. Feeney K, Maguire HC, McClay EF, Sato T, Sondak VK, Toporcer M, Zager JS. Surgically unresectable regional melanoma metastases in a patient with renal failure and peripheral vascular disease: are there safe and potentially effective treatments? Semin Oncol. 2010 Aug; 37(4):303-13. PMID: 20816500.
      Citations:    
    61. Sato T. Locoregional management of hepatic metastasis from primary uveal melanoma. Semin Oncol. 2010 Apr; 37(2):127-38. PMID: 20494705.
      Citations:    
    62. Yamamoto A, Chervoneva I, Sullivan KL, Eschelman DJ, Gonsalves CF, Mastrangelo MJ, Berd D, Shields JA, Shields CL, Terai M, Sato T. High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma. Radiology. 2009 Jul; 252(1):290-8. PMID: 19561263.
      Citations:    
    63. Brody JR, Costantino CL, Berger AC, Sato T, Lisanti MP, Yeo CJ, Emmons RV, Witkiewicz AK. Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle. 2009 Jun 15; 8(12):1930-4. PMID: 19448397.
      Citations:    
    64. Terai M, Tamura Y, Alexeev V, Ohtsuka E, Berd D, Mastrangelo MJ, Sato T. Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential. Cancer Immunol Immunother. 2009 Aug; 58(8):1307-17. PMID: 19142637.
      Citations:    
    65. Sato T, Eschelman DJ, Gonsalves CF, Terai M, Chervoneva I, McCue PA, Shields JA, Shields CL, Yamamoto A, Berd D, Mastrangelo MJ, Sullivan KL. Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 2008 Nov 20; 26(33):5436-42. PMID: 18838710.
      Citations:    
    66. Yamamoto A, Sato T. Locoregional treatment of malignant hepatic tumors with biologic response modifiers. Surg Oncol Clin N Am. 2008 Oct; 17(4):935-55, xii. PMID: 18722927.
      Citations:    
    67. Sato T, Han F, Yamamoto A. The biology and management of uveal melanoma. Curr Oncol Rep. 2008 Sep; 10(5):431-8. PMID: 18706273.
      Citations:    
    68. Shields JA, Shields CL, Materin M, Sato T, Ganguly A. Role of cytogenetics in management of uveal melanoma. Arch Ophthalmol. 2008 Mar; 126(3):416-9. PMID: 18332325.
      Citations:    
    69. Solti M, Berd D, Mastrangelo MJ, Sato T. A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment. Melanoma Res. 2007 Aug; 17(4):225-31. PMID: 17625452.
      Citations:    
    70. Patel K, Sullivan K, Berd D, Mastrangelo MJ, Shields CL, Shields JA, Sato T. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res. 2005 Aug; 15(4):297-304. PMID: 16034309.
      Citations:    
    71. Berd D, Sato T, Maguire HC, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol. 2004 Feb 1; 22(3):403-15. PMID: 14691123.
      Citations:    
    72. Sato T, Terai M, Yasuda R, Watanabe R, Berd D, Mastrangelo MJ, Hasumi K. Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: a new approach to cancer immunotherapy. Cancer Immunol Immunother. 2004 Jan; 53(1):53-61. PMID: 13680192.
      Citations:    
    73. Manne J, Mastrangelo MJ, Sato T, Berd D. TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccine. J Immunol. 2002 Sep 15; 169(6):3407-12. PMID: 12218163.
      Citations:    
    74. Berd D, Sato T, Mastrangelo MJ. Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses. Cancer Immunol Immunother. 2002 Aug; 51(6):320-6. PMID: 12111120.
      Citations:    
    75. Sato T. Locoregional immuno(bio)therapy for liver metastases. Semin Oncol. 2002 Apr; 29(2):160-7. PMID: 11951214.
      Citations:    
    Sato's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (203)
    Explore
    _
    Co-Authors (70)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _